Genetic testing for inherited mutations in endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks for inherited gene changes (mutations) in people with endometrial cancer, especially a gene called BRCA. Finding these mutations may help guide treatment and family risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with endometrial cancer.
- Your tumor has a BRCA mutation (a specific gene change).
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a simple way to test for Lynch syndrome in people with endometrial cancer. Lynch syndrome is an inherited condition that raises the risk of certain cancers, and finding it early can help you and your family with screening and prevention.
This study looks at combining genetic testing with surgical exams to better understand endometrial cancer. It may help doctors see which treatments could work best for you.
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This study tests genetic (DNA) information to help doctors identify ovarian or uterine (endometrial) cancer sooner. You may be asked to do this around the time of planned surgery, when tissue is removed and can be checked for genetic clues.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.